Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ifinatamab deruxtecan |
| Synonyms | |
| Therapy Description |
Ifinatamab deruxtecan (DS-7300a) is a monoclonal antibody targeting B7-H3 (CD276) conjugated to a DNA topoisomerase I inhibitor which may lead to antitumor activities (Ann Oncol (2023) 34 (suppl_2):S481-S482). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ifinatamab deruxtecan | DS7300a|DS 7300a|DS7300|DS 7300|DS-7300|DS-7300a|I-DXd | CD276 Antibody 21 | Ifinatamab deruxtecan (DS-7300a) is a monoclonal antibody targeting B7-H3 (CD276) conjugated to a DNA topoisomerase I inhibitor which may lead to antitumor activities (Ann Oncol (2023) 34 (suppl_2):S481-S482). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
| NCT06203210 | Phase III | Ifinatamab deruxtecan Amrubicin Lurbinectedin Topotecan | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
| NCT06925737 | Phase III | Docetaxel + Prednisone Ifinatamab deruxtecan | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | ESP | DNK | DEU | CZE | CHE | BRA | AUT | AUS | ARG | 12 |
| NCT06863272 | Phase Ib/II | Ifinatamab deruxtecan Docetaxel Abiraterone + Ifinatamab deruxtecan Enzalutamide + Ifinatamab deruxtecan Ifinatamab deruxtecan + ODM-208 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | Recruiting | USA | POL | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 3 |
| NCT06644781 | Phase III | Docetaxel + Irinotecan + Paclitaxel Ifinatamab deruxtecan | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Recruiting | USA | ROU | ITA | FRA | 4 |
| NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
| NCT05280470 | Phase II | Ifinatamab deruxtecan | DS-7300a in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Active, not recruiting | USA | FRA | ESP | DEU | 4 |
| NCT06780137 | Phase Ib/II | HPN328 + Ifinatamab deruxtecan Durvalumab + HPN328 HPN328 Ifinatamab deruxtecan | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Recruiting | USA | TUR | ISR | ESP | AUS | 4 |